Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bickers

Showing results (251-260 of 270) with videos related to

Pageof 27
Sort By:
Plos One|May 15, 2014
Inhibition of p38 MAPK signaling augments skin tumorigenesis via NOX2 driven ROS generationLiang Liu, Hamid Reza Rezvani, Jung Ho Back, et al.
The Journal of Investigative Dermatology|June 17, 2006
Skin retinoid concentrations are modulated by CYP26AI expression restricted to basal keratinocytes in normal human skin and differentiated 3D skin modelsRuth Heise, Jörg Mey, Mark M Neis, et al.
The New England Journal of Medicine|June 8, 2012
Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndromeJean Y Tang, Julian M Mackay-Wiggan, Michelle Aszterbaum, et al.
Toxicology and Applied Pharmacology|August 20, 2013
Unfolded protein response (UPR) signaling regulates arsenic trioxide-mediated macrophage innate immune function disruptionRitesh K Srivastava, Changzhao Li, Sandeep C Chaudhary, et al.
JAMA Dermatology|March 14, 2014
The use of vismodegib to shrink keratocystic odontogenic tumors in patients with basal cell nevus syndromeMina S Ally, Jean Y Tang, Timmy Joseph, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|July 22, 2010
Quantitative risk assessment of contact sensitization: clinical data to assess utility of the modelAnne Marie Api, Donald Belsito, David Bickers, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 21, 2014
Tazarotene: randomized, double-blind, vehicle-controlled, and open-label concurrent trials for basal cell carcinoma prevention and therapy in patients with basal cell nevus syndromeJean Y Tang, Albert S Chiou, Julian M Mackay-Wiggan, et al.
Blood|October 15, 1996
A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group studyJ K Weick, K J Kopecky, F R Appelbaum, et al.
Archives of Internal Medicine|September 1, 1978
Chemotherapy of acute leukemia: a comparison of vincristine, cytarabine, and prednisone alone and in combination with cyclophosphamide or daunorubicinC A Coltman, G P Bodey, J S Hewlett, et al.
Oncotarget|September 29, 2015
Shh and p50/Bcl3 signaling crosstalk drives pathogenesis of BCCs in Gorlin syndromeSandeep C Chaudhary, Xiuwei Tang, Aadithya Arumugam, et al.
Pageof 27

Showing results (251-260 of 270) with videos related to

Sort By:
Pageof 27
Plos One|May 15, 2014
Inhibition of p38 MAPK signaling augments skin tumorigenesis via NOX2 driven ROS generationLiang Liu, Hamid Reza Rezvani, Jung Ho Back, et al.
The Journal of Investigative Dermatology|June 17, 2006
Skin retinoid concentrations are modulated by CYP26AI expression restricted to basal keratinocytes in normal human skin and differentiated 3D skin modelsRuth Heise, Jörg Mey, Mark M Neis, et al.
The New England Journal of Medicine|June 8, 2012
Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndromeJean Y Tang, Julian M Mackay-Wiggan, Michelle Aszterbaum, et al.
Toxicology and Applied Pharmacology|August 20, 2013
Unfolded protein response (UPR) signaling regulates arsenic trioxide-mediated macrophage innate immune function disruptionRitesh K Srivastava, Changzhao Li, Sandeep C Chaudhary, et al.
JAMA Dermatology|March 14, 2014
The use of vismodegib to shrink keratocystic odontogenic tumors in patients with basal cell nevus syndromeMina S Ally, Jean Y Tang, Timmy Joseph, et al.
Dermatitis : Contact, Atopic, Occupational, Drug|July 22, 2010
Quantitative risk assessment of contact sensitization: clinical data to assess utility of the modelAnne Marie Api, Donald Belsito, David Bickers, et al.
Cancer Prevention Research (Philadelphia, Pa.)|January 21, 2014
Tazarotene: randomized, double-blind, vehicle-controlled, and open-label concurrent trials for basal cell carcinoma prevention and therapy in patients with basal cell nevus syndromeJean Y Tang, Albert S Chiou, Julian M Mackay-Wiggan, et al.
Blood|October 15, 1996
A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group studyJ K Weick, K J Kopecky, F R Appelbaum, et al.
Archives of Internal Medicine|September 1, 1978
Chemotherapy of acute leukemia: a comparison of vincristine, cytarabine, and prednisone alone and in combination with cyclophosphamide or daunorubicinC A Coltman, G P Bodey, J S Hewlett, et al.
Oncotarget|September 29, 2015
Shh and p50/Bcl3 signaling crosstalk drives pathogenesis of BCCs in Gorlin syndromeSandeep C Chaudhary, Xiuwei Tang, Aadithya Arumugam, et al.
Pageof 27